2022 (5 POSTS)
Tice RR, Bassan A, Amberg A, Anger LT, Beal MA, Bellion P, Benigni R, Birmingham J…, Mihalchik-Burhans AL , et al. 2021. In silico approaches in carcinogenicity hazard assessment: Current status and future needs. Comp Toxicol 20(Nov):100191; doi: 10.1016/j.comtox.2021.100191 .
View Abstract
Publication: Manuscripts
2021 (6 POSTS)
Hackshaw A, Cohen SS, Reichert H , Kansal AR, Chung KC, Ofman JJ. 2021. Estimating the population health impact of a multi-cancer early detection genomic blood test to complement existing screening in the US and UK. Brit J Cancer, open access .
View Abstract
Publication: Manuscripts
Yin W, Nie Z, Dingley K , Trzoss M, Krilov G, Marshall N et al. 2021. Characterization of potent paracaspase MALT1 inhibitors for hematological malignancies. Blood 138 (Supplement 1):1187; doi: 10.1182/blood-2021-153159 .
View Abstract
Publication: Manuscripts
Proctor DM , Bhat V, Suh M , Reichert H , Jiang X , Thompson CM . 2021. Inhalation cancer risk assessment for environmental exposure to hexavalent chromium: Comparison of margin-of-exposure and linear extrapolation approaches. Regul Toxicol Pharmacol 124(August):104969; doi: 10.1016/j.yrtph.2021.104969 .
View Abstract
Publication: Manuscripts
Alexander DD, Pastula ST , Riordan AS. 2021. Epidemiology of lung cancer among acrylonitrile-exposed study populations: A meta-analysis. Regul Toxicol Pharmacol 122(June):104896; doi: 10.1016/j.yrtph.2021.104896 . PMID: 33617939.
View Abstract
Publication: Manuscripts
Bylsma L , Nielson C, Fryzek J, Saad H, Crawford J. Edit chemotherapy relative dose intensity, overall survival, and hematologic toxicity in solid-tumor cancer patients: A literature review and meta-analysis. Poster presentation [preview ] at 37th ICPE (International Conference on Pharmacoepidemiology & Therapeutic Rick Management), Virtual, August 2021.
View Abstract
Publication: Abstracts and Presentations
Ierardi AM, Lotter JT, Jacobs N, Finley BL , Pierce JS. Derivation of a proposed asbestiform tremolite NOAEL for lung cancer. Virtual poster Presentation at Society of Toxicology 60th Annual Meeting, Virtual, 2021.
Publication: Abstracts and Presentations
2020 (16 POSTS)
Levin-Sparenberg E, Bylsma LC , Lowe K, Sangare L, Fryzek JP, Alexander DD. 2020. A systematic literature review and meta-analysis describing the prevalence of KRAS, NRAS, and BRAF gene mutations in metastatic colorectal cancer. Gastroenterol Res 13(5):184–198; doi: 10.14740/gr1167 .
View Abstract
Publication: Manuscripts
Cohen S, Reichert H , Kansal AR, Chung KC. Improved efficiency of cancer screening with multi-cancer early detection test. International Society for Pharmacoeconomics and Outcomes Research, Inc. (ISPOR) Virtual Conference, May 2020.
Publication: Abstracts and Presentations
Bylsma LC , Gillezeau C, Garawin TA, Kelsh MA , Fryzek JP, Sangaré L, et al. 2020. Prevalence of RAS and BRAF mutations in metastatic colorectal cancer patients by tumor sidedness: A systematic review and meta-analysis. Cancer Med 9(3):1044–1057.
View Abstract
Publication: Manuscripts
Li S, Liu J, Gong T, Guo H, Gawade PL, Kelsh MA , et al. 2020. Duration of short-acting granulocyte colony-stimulating factor for primary prophylaxis and risk of neutropenia-related hospitalization in older patients with cancer. J Geriatr Oncol 11(8):1309–1315.
View Abstract
Publication: Manuscripts
Li S, Peng Y, Liu J, Li S, Raskin L, Kelsh MA , et al. Variations in hospitalization and emergency department/observation stays using the oncology care model methodology in Medicare data. 2020. Curr Med Res Opin 36(9):1519–1527.
View Abstract
Publication: Manuscripts
Gawade PL, Li S, Henry D, Smith N, Belani R, Kelsh MA , et al. Patterns of granulocyte colony-stimulating factor prophylaxis in patients with cancer receiving myelosuppressive chemotherapy. 2020. Support Care Cancer 28(9):4413–4424.
View Abstract
Publication: Manuscripts
Hawkins A, Murphy A, McNamara M, Gawade PL, Belani R, Kelsh MA . 2020. A survey of oncologists’ perceptions and opinions regarding the use of granulocyte colony-stimulating factors. J Cancer Edu 35(1):178–186.
View Abstract
Publication: Manuscripts
Locatelli F, Whitlock JA, Peters C, Chen-Santel C, Chia V, Dennis RM, … Kelsh MA , et al. 2020. Blinatumomab versus historical standard therapy in pediatric patients with relapsed/refractory Ph-negative B-cell precursor acute lymphoblastic leukemia. Leukemia 34(9):2473–2478.
View Abstract
Publication: Manuscripts
Ravandi F, Pierce S, Garcia-Manero G, Kadia T, Jabbour E, Borthakur G, … Kelsh M , et al. 2020. Salvage therapy outcomes in a historical cohort of patients with relapsed or refractory acute myeloid leukemia. Clin Lymphoma Myeloma Leuk 20(11):e871–e882.
View Abstract
Publication: Manuscripts
Lafranconi M, Budinsky R, Corey L, Haws L , Klapacz J, Chappell G, Golden R. Exposure to 1,4-dioxane above the metabolic saturation threshold induces a mitogenic key element in the mouse liver cancer mode of action. Abstract #1505. Society of Toxicology 59th Annual Meeting, Virtual, 2020.
View Abstract
Publication: Abstracts and Presentations
Elbeddini A, Hooda N , Gazarin M, Webster P, McMillan J. 2020. Irinotecan-associated dysarthria in patients with pancreatic cancer: A single site experience. Am J Case Rep 21:e924058; doi: 10.12659/AJCR.924058 . PMID: 32594093.
View Abstract
Publication: Manuscripts
Jensen IS, Hathway J, Cyr PL , Gauden D, Gardiner P. 2020. Cost–consequence analysis of 18 F-fluciclovine for the staging of recurrent prostate cancer. J Mark Access Health Pol 8(1):1749362; doi: 10.1080/20016689.2020.1749362 .
View Abstract
Publication: Manuscripts
Bylsma LC , Dean R, Lowe K, Sangare L, Alexander D, Fryzek J. The incidence of infusion reactions associated with monoclonal antibody drugs targeting the epidermal growth factor receptor in metastatic colorectal cancer patients: A systematic literature review and meta-analysis of patient and study characteristics. Poster for Society of Toxicology 59th Annual Meeting, Virtual, 2020.
View Abstract